CHEK2 and breast cancer: In two recent large studies, the prevalence of CHEK2 GPVs was reported to be 1.44% and 1.08% in BC patients and 0.62% and 0.42% in unaffected control women by Dorling et al. and Hu et al., respectively [10,11].